| 报告题目 | Rational design of responsive biomaterials for cancer imaging and therapy |
| 报告人 | Dr. ZHOU Kejin |
| 报告人单位 | Simmons Comprehensive Cancer Center, UT Southwestern Medical Center |
| 报告时间 | 2016-08-12 |
| 报告地点 | 合肥微尺度物质科学国家实验室九楼会议室（9004） |
| 主办单位 | 合肥微尺度物质科学国家实验室 |
| 报告介绍 | Abstract:
The first part of my talk will focus on work completed during my first round of postdoctoral training at UT southwestern Medical Center aimed at the development of a universal new imaging method to detect various types of cancers. The sensitivity of the most current cancer imaging methods is limited by over-expression of cancer biomarkers, such as the Her2/neu receptor and the folate receptor. Regardless of the cancer type, tumor growth results in the formation of a microenvironment with weak pathophysiological signals, which provides a great opportunity to establish a universal cancer imaging method. The key is to develop an ultra sensitive way to amplify these weak tumor microenvironment signals for use in a clinical setting.Through rational design of macromolecule structures, we synergized an ultra pH-sensitive de-micellization process with an ultra-sensitive distance-induced de-quenching fluorescent mechanism. We successfully established a nanoplatform with an ON/OFF signal amplification in less than 0.25 pH units. Our ultra pH-sensitive fluorescent nanoplatform amplifies the weak signals of angiogenesis and of abnormal tumor acidity for the detection of solid cancers regardless of the cancer type.
The second part of my talk will focus on our ongoing effort at UT southwestern Medical Center aimed at advancing delivery technologies of small RNAs towards clinical cancer treatment. Tremendous progress has been made with regard to delivery efficacy of small RNAs, but RNA-based cancer therapies are hindered by the lack of delivery carriers that avoid exacerbating cancer-induced organ dysfunction. Liver cancer is a leading cause of cancer-related death worldwide, with 70% caused by hepatocellular carcinoma. Unfortunately, five small-molecule drugs for hepatocellular carcinoma recently failed phase III clinical trials, because late-stage liver dysfunction amplifies drug toxicity. To achieve a balance between potency and toxicity with small RNA carriers, we designed a modular dendrimer library to incorporate ester bonds to minimize dendrimer toxicity. Then, we changed the chemical structure of the dendrimers to establish an in vivo structure-activity relationship. This design establishes a library of more than 1,500 degradable dendrimers through two sequential, orthogonal reactions without purification procedures. We discovered highly effective dendrimer carriers that can deliver small RNAs to tumor cells without adverse toxicity in late-stage liver cancer, resulting in pronounced survival benefits in a well-established aggressive MYC-driven murine liver cancer model. In my talk, I will describe the various influential parameters we have discovered to be critical to the effective design and fabrication of response biomaterials for cancer imaging and therapy. 报告人简介：
Dr. Kejin Zhou 2009 毕业于上海有机所获博士学位，毕业后在Simmons Comprehensive Cancer Center, UT Southwestern Medical Center 进行博士后研究工作至今。Dr. Kejin Zhou
已在PNAS, Nature Materials, JACS, Angewandte Chemie 等国际知名期刊发表论文13篇 |
